Drug:
Reaction: EXPOSURE VIA SKIN CONTACT
20260101 - 20261231
No. 201 - 300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 201 | 26915875 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 202 | 26915937 |
US |
17 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 203 | 26915953 |
US |
84 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 204 | 26915976 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 205 | 26916298 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 206 | 26916317 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 207 | 26916957 |
US |
2 | |
Injection site urticaria, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 208 | 26917029 |
US |
36 | 2 |
Accidental exposure to product, Exposure via skin contact, Feeling abnormal, |
||||
ETANERCEPT, |
||||
| 209 | 26917311 |
US |
58 | 1 |
Off label use, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 210 | 26917317 |
US |
59 | 2 |
Injection site pain, Product use in unapproved indication, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE TABLETS, SIMVASTATIN, LOSARTAN POTASSIUM, LOSARTAN, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 211 | 26918784 |
US |
76 | 2 |
Exposure via skin contact, Wrong technique in device usage process, Incorrect dose administered by device, Accidental exposure to product, Incorrect dose administered, |
||||
MEPOLIZUMAB, |
||||
| 212 | 26919494 |
US |
9 | 1 |
Injury associated with device, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 213 | 26921025 |
US |
84 | 1 |
Accidental exposure to product, Exposure via skin contact, Incorrect disposal of product, Incorrect dose administered by device, Device monitoring procedure not performed, Product communication issue, |
||||
EVOLOCUMAB, |
||||
| 214 | 26909512 |
US |
7 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 215 | 26909880 |
US |
58 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 216 | 26909895 |
US |
2 | |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 217 | 26909914 |
US |
1 | |
Accidental exposure to product, Device difficult to use, Exposure via skin contact, |
||||
ERENUMAB-AOOE, |
||||
| 218 | 26910113 |
US |
75 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 219 | 26910291 |
US |
15 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 220 | 26910293 |
US |
80 | |
Injection site swelling, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 221 | 26910309 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 222 | 26910321 |
US |
11 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 223 | 26910420 |
US |
41 | 2 |
Wrong technique in product usage process, Accidental exposure to product, Exposure via skin contact, |
||||
ETANERCEPT, ETANERCEPT, |
||||
| 224 | 26910422 |
US |
2 | |
Exposure via skin contact, Accidental exposure to product, Product complaint, |
||||
FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, |
||||
| 225 | 26910527 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 226 | 26910549 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 227 | 26910556 |
US |
11 | 1 |
Injection site bruising, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 228 | 26910815 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 229 | 26910816 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 230 | 26910824 |
US |
86 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 231 | 26910850 |
US |
40 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 232 | 26910971 |
US |
74 | 1 |
Exposure via skin contact, Device use error, Accidental exposure to product, Product dose omission in error, Product administration interrupted, |
||||
MEPOLIZUMAB, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 233 | 26911101 |
US |
2 | |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 234 | 26911111 |
US |
51 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 235 | 26911515 |
US |
37 | 2 |
Injection site haemorrhage, Injection site bruising, Accidental exposure to product, Exposure via skin contact, Needle issue, |
||||
DUPILUMAB, |
||||
| 236 | 26911534 |
US |
13 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, ERGOCALCIFEROL, METHYLPHENIDATE HYDROCHLORIDE, LORATADINE, LORATADINE ORAL, FLUOXETINE HYDROCHLORIDE, |
||||
| 237 | 26911560 |
US |
79 | 2 |
Injection site rash, Injection site erythema, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, MORPHINE SULFATE, METOPROLOL TARTRATE, METOROPROLOL TARTRATE, METOPROLOL, ABALOPARATIDE, ALPRAZOLAM, |
||||
| 238 | 26911563 |
US |
85 | 1 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, Device issue, |
||||
DUPILUMAB, |
||||
| 239 | 26911565 |
US |
72 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 240 | 26911958 |
US |
57 | 1 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 241 | 26912342 |
US |
51 | 2 |
Injury associated with device, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 242 | 26912346 |
US |
35 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 243 | 26912350 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 244 | 26912359 |
US |
64 | 2 |
Injection site pain, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 245 | 26912383 |
US |
66 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 246 | 26912396 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 247 | 26912701 |
US |
30 | 2 |
Occupational exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 248 | 26912711 |
US |
65 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 249 | 26912712 |
US |
44 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 250 | 26913318 |
US |
39 | 2 |
Inappropriate schedule of product administration, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 251 | 26913669 |
US |
64 | 2 |
Device difficult to use, Accidental exposure to product, Exposure via skin contact, Drug dose omission by device, |
||||
ERENUMAB-AOOE, |
||||
| 252 | 26913812 |
US |
43 | 2 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 253 | 26913818 |
US |
90 | 1 |
Injury associated with device, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 254 | 26913819 |
US |
70 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 255 | 26913992 |
US |
73 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 256 | 26914014 |
US |
72 | 1 |
Injury associated with device, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 257 | 26914119 |
US |
55 | 1 |
Injection site induration, Underdose, Exposure via skin contact, Wrong technique in product usage process, Device issue, |
||||
SIBEPRENLIMAB, SIBEPRENLIMAB, |
||||
| 258 | 26914174 |
US |
2 | |
Product delivery mechanism issue, Product dispensing issue, Exposure via skin contact, |
||||
OLOPATADINE HYDROCHLORIDE, |
||||
| 259 | 26914207 |
US |
||
Product design issue, Liquid product physical issue, Product container seal issue, Product leakage, Product use complaint, Exposure via skin contact, |
||||
OLOPATADINE HYDROCHLORIDE, |
||||
| 260 | 26914276 |
US |
6 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 261 | 26914373 |
GB |
33 | |
Depression, Feeling hot, Heat stroke, Pain, Therapeutic response shortened, Exposure via skin contact, Accidental exposure to product, Product administration error, Wrong technique in product usage process, Product dose omission issue, Inappropriate schedule of product administration, Off label use, Therapy interrupted, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 262 | 26914504 |
US |
73 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 263 | 26914521 |
US |
63 | 1 |
Accidental exposure to product, Exposure via skin contact, Product administration error, Wrong technique in product usage process, |
||||
EVOLOCUMAB, |
||||
| 264 | 26914567 |
US |
71 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 265 | 26904530 |
US |
75 | 2 |
Injection site haemorrhage, Injection site pain, Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 266 | 26904689 |
US |
86 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 267 | 26904887 |
US |
10 | 2 |
Accidental exposure to product, Exposure via skin contact, Injury associated with device, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 268 | 26904892 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 269 | 26904982 |
US |
76 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
EVOLOCUMAB, |
||||
| 270 | 26905087 |
US |
32 | 2 |
Injection site swelling, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 271 | 26905090 |
US |
46 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 272 | 26905634 |
US |
47 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 273 | 26906020 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 274 | 26906029 |
US |
10 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 275 | 26906031 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
SARILUMAB, |
||||
| 276 | 26906051 |
US |
84 | 2 |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, Product dose omission issue, |
||||
MEPOLIZUMAB, |
||||
| 277 | 26906062 |
US |
72 | 2 |
Paralysis, Drug ineffective, Exposure via skin contact, Accidental exposure to product, Product use complaint, |
||||
PERFLUOROHEXYLOCTANE, LOSARTAN, HYDROCHLOROTHIAZIDE, CARBAMAZEPINE, |
||||
| 278 | 26906064 |
US |
78 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 279 | 26906303 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 280 | 26906307 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 281 | 26906343 |
US |
63 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 282 | 26906350 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 283 | 26906694 |
US |
68 | 1 |
Injection site swelling, Device issue, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 284 | 26906702 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 285 | 26906725 |
US |
2 | 2 |
Injury associated with device, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 286 | 26907012 |
US |
51 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
ETANERCEPT, |
||||
| 287 | 26907047 |
US |
11 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 288 | 26907055 |
US |
27 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 289 | 26907063 |
US |
80 | 1 |
Injection site pain, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 290 | 26907068 |
US |
42 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 291 | 26907076 |
US |
84 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 292 | 26907078 |
US |
83 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 293 | 26907537 |
US |
77 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 294 | 26907550 |
US |
56 | 2 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 295 | 26907579 |
US |
2 | |
Illness, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ALBUTEROL SULFATE, BUSPIRONE HYDROCHLORIDE, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, HYDROCORTISONE, EPINEPHRINE, ADRENALINUM, ERYTHROMYCIN, FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE ORAL, FEXOFENADINE HCL, GABAPENTIN, HYDROCHLOROTHIAZIDE, LATANOPROST, METHIMAZOLE, OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE OPHTHALMIC, OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ROSUVASTATIN CALCIUM, PRAMOXINE HYDROCHLORIDE, VALSARTAN, VALSARTAN ORAL, |
||||
| 296 | 26907836 |
US |
71 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 297 | 26907845 |
US |
38 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 298 | 26907847 |
US |
17 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 299 | 26907868 |
US |
72 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 300 | 26908151 |
US |
43 | 1 |
Migraine, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30